Veru Inc. (NASDAQ:VERU - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Veru in a research note issued to investors on Thursday, January 9th. B. Riley analyst W. Wood forecasts that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Veru's current full-year earnings is ($0.30) per share. B. Riley also issued estimates for Veru's Q2 2025 earnings at ($0.05) EPS.
Veru (NASDAQ:VERU - Get Free Report) last released its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%.
Several other research firms have also weighed in on VERU. HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reaffirmed an "outperform" rating and set a $5.00 target price on shares of Veru in a research note on Tuesday, November 5th.
View Our Latest Stock Report on VERU
Veru Stock Up 7.7 %
Shares of NASDAQ:VERU opened at $0.78 on Monday. The company has a market cap of $114.44 million, a P/E ratio of -1.63 and a beta of -0.53. The company's fifty day moving average is $0.69 and its two-hundred day moving average is $0.80. Veru has a 12-month low of $0.36 and a 12-month high of $1.92.
Hedge Funds Weigh In On Veru
Hedge funds have recently modified their holdings of the stock. Zacks Investment Management acquired a new stake in Veru during the third quarter valued at $25,000. Gladstone Institutional Advisory LLC raised its stake in shares of Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company's stock worth $44,000 after purchasing an additional 14,500 shares in the last quarter. Weaver Consulting Group lifted its holdings in shares of Veru by 41.0% during the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company's stock valued at $45,000 after buying an additional 20,280 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Veru by 185.9% in the 3rd quarter. SG Americas Securities LLC now owns 66,128 shares of the company's stock valued at $51,000 after buying an additional 42,997 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Veru by 142.8% in the third quarter. Jane Street Group LLC now owns 96,454 shares of the company's stock worth $74,000 after buying an additional 56,736 shares during the last quarter. 47.16% of the stock is owned by institutional investors and hedge funds.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
